Collagen Solutions Plc Secure base, and opportunities intact

Hardman & Co ReportCollagen Solutions Plc (LON:COS) is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, regenerative medicine, and in vitro diagnostic products. It aims to grow organically and through acquisition to take the business closer to the end-product margin. While the majority of sales are secure, visibility and timing of new business is less certain. Therefore, our forecasts are based on a more conservative approach for coming years. Recently added commercial and operational firepower provides greater support and reassurance that new opportunities will convert, allowing revised forecasts to be exceeded.

► Strategy: COS supplies value-added bio-functional collagen and provides R&D and contract manufacturing services to a broad range of international clients. Its growth strategy is to expand the client base organically and through acquisitions to take the company further up the value added chain.

► Changes to forecasts: For new opportunities, COS has limited control over the decisions, buying patterns and regulatory position of clients, making forecasting difficult. A more conservative view on conversion of new business over the next 3 years reduces forecasts markedly (24-52%), although EBITDA is less affected.

► Valuation: The cut in medium-term forecasts has a significant effect on our DCF valuation, as near-term changes have a disproportionate influence. Our NPV of the enterprise has fallen from £73m to £46m, or from 39p to 26p per share. 97% of this value is derived from the terminal value, given the short-term cash burn.

► Risks: Recurring revenues are secure, but the exact timing of new development, manufacturing, and supply agreements is less certain. Changes to customer project timelines and regulatory delays remains a source of risk. Route to Chondromimetic commercialisation is currently in early stage planning.

► Investment summary: Management is developing a value added company which will ultimately be reflected in the valuation. Collagen Solutions Plc is reviewing new opportunities, which include a China JV and cartilage repair product Chondromimetic – however, the company remains sensitive to the short-term buying activities of its new customers.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Collagen Solutions Targeting long-term sustainable growth

    Collagen Solutions Plc (LON:COS) is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced to accelerate the rate

    Hardman & Co

    Collagen Solutions Engineering towards CE Mark

    Collagen Solutions Plc (LON:COS) is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced recently to accelerate the

    Hardman & Co

    Collagen Solutions Plc Engineering cartilage repairs

    Collagen Solutions Plc (LON:COS) is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced over the last year

    Hardman & Co

    Collagen Solutions Plc Focus on R&D

    Collagen Solutions Plc (LON:COS) is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, in vitro diagnostics, and regenerative medicine. The strategic plan is to invest into its own pipeline

    DirectorsTalk

    Panmure Gordon thoughts on Collagen Solutions this morning

    Panmure Gordon Analyst Dr Mike Mitchell said this morning on Collagen Solutions: “Prelim results have delivered a performance in-line with our expectations. The company reports revenue and other income of £1.04m (PGe £1.0m, 2014: £0.02m) and

    DirectorsTalk

    Collagen Solutions plc final results with increased revenue

    Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, has given DirectorsTalk its final results for the year ended 31 March